Scarica l'app Stockscreener
4.77
0.83%
-0.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.81
Aprire:
$4.855
Volume 24 ore:
1.60M
Relative Volume:
1.43
Capitalizzazione di mercato:
$917.39M
Reddito:
$12.99M
Utile/perdita netta:
$-74.39M
Rapporto P/E:
-10.84
EPS:
-0.44
Flusso di cassa netto:
$-78.92M
1 W Prestazione:
-0.21%
1M Prestazione:
+14.39%
6M Prestazione:
+49.53%
1 anno Prestazione:
+44.98%
Intervallo 1D:
$4.645
$4.975
Intervallo di 1 settimana:
$4.55
$5.05
Portata 52W:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Nome
Arbutus Biopharma Corp
Settore
Industria
Telefono
604-419-3200
Indirizzo
701 VETERANS CIRCLE, WARMINSTER, PA
Confronta ABUS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.77 | 925.08M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-02-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-02-25 | Iniziato | Jefferies | Hold |
| 2020-12-17 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-27 | Ripresa | JMP Securities | Mkt Outperform |
| 2020-07-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-03-06 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | Iniziato | Robert W. Baird | Outperform |
| 2020-02-05 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | Reiterato | B. Riley FBR | Buy |
| 2019-10-04 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2018-10-12 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-06 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | Ripresa | Chardan Capital Markets | Buy |
| 2018-03-19 | Downgrade | Wedbush | Outperform → Neutral |
| 2018-01-05 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | Reiterato | Wedbush | Outperform |
| 2016-12-13 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
Mostra tutto
Arbutus Biopharma Corp Borsa (ABUS) Ultime notizie
Arbutus Biopharma's CFO David Hastings sells shares worth $72,826 - MSN
Arbutus Biopharma (NASDAQ:ABUS) Shares Up 6%Still a Buy? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell? - Defense World
Why Arbutus Biopharma Corporation stock is rated strong buyEarnings Recap Summary & Fast Moving Market Watchlists - Улправда
ABUS (Arbutus Biopharma) OCF Margin % : -1,099.62% (As of Sep. 2025) - GuruFocus
How sustainable is Arbutus Biopharma Corporation stock dividend payout2025 Earnings Impact & Community Trade Idea Sharing Platform - Улправда
Is Arbutus Biopharma Corporation stock ready for breakoutCEO Change & Reliable Entry Point Alerts - ulpravda.ru
Does Arbutus Biopharma Corporation stock trade at a discount to peersPortfolio Update Report & Weekly Watchlist of Top Performers - Улправда
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.4%What's Next? - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Trading Up 6.6%Should You Buy? - MarketBeat
BlackBarn Capital Partners LP Boosts Stock Position in Arbutus Biopharma Corporation $ABUS - MarketBeat
A Look at Arbutus Biopharma Corp (ABUS) Shares in the Recent Past Indicates Growth - setenews.com
Arbutus Biopharma Corp Discusses Ongoing Patent Litigation - TradingView — Track All Markets
[8-K] Arbutus Biopharma Corp Reports Material Event | ABUS SEC FilingForm 8-K - Stock Titan
Arbutus Biopharma Corporation $ABUS Shares Purchased by Two Seas Capital LP - MarketBeat
New Haven biotech names new CFO - Hartford Business Journal
The time has not yet come to remove your chips from the table: Arbutus Biopharma Corp (ABUS) - setenews.com
Why global investors buy Arbutus Biopharma Corporation (I9DN) stockWeekly Trend Summary & Community Supported Trade Ideas - Newser
Can Arbutus Biopharma Corporation (I9DN) stock hold up in economic slowdown2025 Year in Review & Real-Time Stock Entry Alerts - Newser
Is Arbutus Biopharma Corporation (I9DN) stock a buy for dividend portfoliosPortfolio Value Report & Fast Moving Stock Trade Plans - Newser
Arbutus Biopharma (ABUS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
How Arbutus Biopharma Corporation (I9DN) stock trades after earningsJuly 2025 Short Interest & Capital Efficiency Focused Strategies - Newser
Why Arbutus Biopharma Corporation (I9DN) stock could outperform next yearJuly 2025 Short Interest & Safe Capital Allocation Plans - Newser
There is no way Arbutus Biopharma Corp (ABUS) can keep these numbers up - setenews.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving AverageHere's What Happened - MarketBeat
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200 Day Moving Average – Here’s What Happened - Defense World
How Arbutus Biopharma Corporation (I9DN) stock reacts to new regulationsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A look into Arbutus Biopharma Corp (ABUS)’s deeper side - Setenews
Why Arbutus Biopharma Corporation stock is trending among retail tradersJuly 2025 Volume & Daily Growth Stock Tips - newser.com
Arbutus Reports Major Advances in HBV Candidate as Litigation Against Moderna, Pfizer Builds Toward Trial - MyChesCo
Arbutus Biopharma Corporation stock trend outlook and recovery pathQuarterly Market Summary & Daily Price Action Insights - newser.com
How Arbutus Biopharma Corporation (I9DN) stock compares with market leadersWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
How Arbutus Biopharma Corporation stock compares to growth peersMarket Risk Analysis & Fast Moving Trade Plans - newser.com
Arbutus Biopharma’s (ABUS) Buy Rating Reiterated at Chardan Capital - Defense World
Quantitative breakdown of Arbutus Biopharma Corporation recent move2025 Big Picture & Reliable Intraday Trade Plans - newser.com
Arbutus Biopharma (NASDAQ:ABUS) Given Buy Rating at Chardan Capital - MarketBeat
What indicators show strength in Arbutus Biopharma Corporation2025 Investor Takeaways & Low Volatility Stock Recommendations - newser.com
What analysts say about Arbutus Biopharma Corporation I9DN stockBull Market Opportunities & Follow Top Performers in the Community - earlytimes.in
Arbutus Biopharma (ABUS) Receives Steady Buy Rating from Chardan Capital | ABUS Stock News - GuruFocus
Arbutus Biopharma Faces Losses And Legal Battles This Quarter - Finimize
Arbutus: Q3 Earnings Snapshot - New Haven Register
Arbutus Biopharma earnings missed, revenue fell short of estimates By Investing.com - Investing.com South Africa
Arbutus Biopharma shares rise as imdusiran data shows promising results By Investing.com - Investing.com Canada
Arbutus Biopharma shares rise as imdusiran data shows promising results - Investing.com
Arbutus Biopharma Corp Azioni (ABUS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):